Endoscopic Shunts Embolization for Refractory Hepatic Encephalopathy (NCT07553858)
Endoscopic Ultrasound Embolization of Porto-Systemic Shunt for Management of Medically Refractory Hepatic Encephalopathy: A Randomized Trial
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to learn if endoscopic ultrasound guided (EUS guided) spontaneous porto-systemic shunt (SPSS) embolization works to treat refractory hepatic encephalopathy in adults. It will also learn about the safety of EUS guided embolization. The main questions it aims to answer are: 1. Does EUS guided embolization maintain an acceptable safety profile? 2. Does EUS guided embolization of large SPSS result in significant clinical improvement in patients with refractory hepatic encephalopathy? Participants will: 1. Receive EUS guided embolization or medical management. 2. Receive follow-up EUS procedures one month after embolization for assessment of the shunt patency and development of varices (embolization group). 3. Receive follow-up every week for 4 weeks to assess degree of worst episode of hepatic encephalopathy via West Haven criteria.
Who can join: Review the eligibility criteria below.
Location: Rutgers University Hospital — Newark, New Jersey
Age range: 18 Years
🧪 Interventions in This Study
- Endoscopic ultrasound-guided transgastric embolization of the spontaneous portosystemic shunts (PROCEDURE)
- Interventional Radiology for shunt embolization/retrograde tranvenous obliteration (PROCEDURE)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Rutgers University Hospital — Newark, New Jersey
📞 Contact the Study Coordinator
Phone: (973) 972-9814
Email: kh852@njms.rutgers.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hepatic Encephalopathy
- Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis — Homewood, Alabama
- Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis — Dothan, Alabama
- Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy — Boston, Massachusetts
- Revealing Engagement Patterns Among Hepatic Encephalopathy Patients — San Francisco, California
- Microbiota trAnSplant ThERaPy In hEpatiC Encephalopathy (MASTERPIECE) — West Haven, Connecticut
Explore by condition: All Hepatic Encephalopathy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.